Essential Thrombocythemia News

Essential Thrombocythemia	Welcome, Profile Billing Logout

«1 2 345 »

||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte
Enrollment open:  Ruxolitinib Prior to Transplant in Patients With Myelofibrosis (clinicaltrials.gov) -  Apr 21, 2013
P2, N=86, Recruiting,  Sponsor: John Mascarenhas
Not yet recruiting --> Recruiting

||||||||||  luminespib (AUY922) / Ligand
Enrollment open:  HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET (clinicaltrials.gov) -  Apr 17, 2013
P2, N=25, Recruiting,  Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Recruiting Suspended --> Recruiting

||||||||||  Ojjaara (momelotinib) / GSK
Trial completion:  Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) (clinicaltrials.gov) -  Apr 16, 2013
P1/2, N=166, Completed,  Sponsor: Gilead Sciences
Suspended --> Recruiting Active, not recruiting --> Completed

|||||||||| Trial termination: Studying Fentanyl in Patients With Cancer (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=2, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Terminated; poor accrual

|||||||||| Enrollment change: Studying Fentanyl in Patients With Cancer (clinicaltrials.gov) - Apr 15, 2013
P=N/A, N=2, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Terminated; poor accrual N=20 --> 2

||||||||||  Zolinza (vorinostat) / Merck (MSD)
Trial completion, Combination therapy:  Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders (clinicaltrials.gov) -  Apr 9, 2013
P1, N=25, Completed,  Sponsor: National Cancer Institute (NCI)
N=20 --> 2 Recruiting --> Completed

||||||||||  fresolimumab (GC 1008) / Sanofi
Trial completion:  Anti-TGF-beta Therapy in Patients With Myelofibrosis (clinicaltrials.gov) -  Mar 21, 2013
P1, N=3, Completed,  Sponsor: John Mascarenhas
Recruiting --> Completed Active, not recruiting --> Completed

||||||||||  ifosfamide / Generic mfg., carboplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion:  Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer (clinicaltrials.gov) -  Mar 20, 2013
P1/2, N=30, Completed,  Sponsor: Cancer Treatment Centers of America
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial completion, Metastases: Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 17, 2013
P1/2, N=47, Completed, Sponsor: Asan Medical Center
Active, not recruiting --> Completed Recruiting --> Completed

||||||||||  trimethoprim/sulfamethoxazole / Generic mfg.
Trial withdrawal:  Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies (clinicaltrials.gov) -  Feb 12, 2013
P1/2, N=0, Withdrawn,  Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Not yet recruiting --> Withdrawn

||||||||||  trimethoprim/sulfamethoxazole / Generic mfg.
Enrollment change:  Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies (clinicaltrials.gov) -  Feb 12, 2013
P1/2, N=0, Withdrawn,  Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Withdrawn N=684 --> 0

||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte
New P2 trial:  Ruxolitinib Prior to Transplant in Patients With Myelofibrosis (clinicaltrials.gov) -  Feb 11, 2013
P2, N=86, Recruiting,  Sponsor: John Mascarenhas

|||||||||| Trial completion, Metastases: Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Jan 30, 2013
P1, N=40, Completed, Sponsor: National Cancer Institute (NCI)
N=684 --> 0 Active, not recruiting --> Completed

||||||||||  imatinib / Generic mfg.
Trial completion:  Imatinib Mesylate in Treating Patients With Myelofibrosis (clinicaltrials.gov) -  Dec 20, 2012
P2, N=18, Completed,  Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  cyclosporine / Generic mfg.
Clinical:  Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation (clinicaltrials.gov) -  Dec 9, 2012
P2, N=0, Terminated,  Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Terminated; low study accrual

||||||||||  Estybon (rigosertib) / Onconova, SymBio Pharma, Knight Therap
Enrollment closed:  Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL) (clinicaltrials.gov) -  Nov 27, 2012
P1/2, N=34, Active, not recruiting,  Sponsor: Onconova Therapeutics, Inc.
Active, not recruiting --> Terminated; low study accrual Recruiting --> Active, not recruiting

||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte
New P2 trial:  Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis (clinicaltrials.gov) -  Nov 20, 2012
P2, N=28, Recruiting,  Sponsor: Mayo Clinic

||||||||||  saridegib oral (IPI 926 oral) / Infinity Pharma
Enrollment change:  A Phase 2 Study With IPI-926 in Patients With Myelofibrosis (clinicaltrials.gov) -  Nov 13, 2012
P2, N=14, Completed,  Sponsor: Infinity Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting N=35 --> 14

||||||||||  pracinostat (SB939) / Helsinn, MEI, Menarini
Enrollment change, Epigenetic controller:  Study of SB939 in Subjects With Myelofibrosis (clinicaltrials.gov) -  Nov 13, 2012
P2, N=23, Completed,  Sponsor: M.D. Anderson Cancer Center
N=35 --> 14 N=41 --> 23

||||||||||  saridegib oral (IPI 926 oral) / Infinity Pharma
Trial completion:  A Phase 2 Study With IPI-926 in Patients With Myelofibrosis (clinicaltrials.gov) -  Nov 13, 2012
P2, N=14, Completed,  Sponsor: Infinity Pharmaceuticals, Inc.
N=41 --> 23 Active, not recruiting --> Completed

||||||||||  pracinostat (SB939) / Helsinn, MEI, Menarini
Trial completion, Epigenetic controller:  Study of SB939 in Subjects With Myelofibrosis (clinicaltrials.gov) -  Nov 13, 2012
P2, N=23, Completed,  Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  cyclophosphamide / Generic mfg.
Trial completion:  Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders (clinicaltrials.gov) -  Oct 23, 2012
P2, N=72, Completed,  Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte, ruxolitinib sustained release (INCB018424 SR) / Incyte
Trial completion:  Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients (clinicaltrials.gov) -  Oct 21, 2012
P2, N=41, Completed,  Sponsor: Incyte Corporation
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Campath (alemtuzumab) / Sanofi
Trial termination:  MPDMDSBMT: Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML (clinicaltrials.gov) -  Oct 4, 2012
P2, N=7, Terminated,  Sponsor: Baylor College of Medicine
Active, not recruiting --> Completed Active, not recruiting --> Terminated; Closed due to competing protocols

||||||||||  Campath (alemtuzumab) / Sanofi
Enrollment change:  MPDMDSBMT: Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML (clinicaltrials.gov) -  Oct 4, 2012
P2, N=7, Terminated,  Sponsor: Baylor College of Medicine
Active, not recruiting --> Terminated; Closed due to competing protocols N=44 --> 7

||||||||||  Inrebic (fedratinib) / BMS
Enrollment closed:  Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis (clinicaltrials.gov) -  Oct 1, 2012
P3, N=225, Active, not recruiting,  Sponsor: Sanofi
N=44 --> 7 Recruiting --> Active, not recruiting

|||||||||| Trial completion: Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer (clinicaltrials.gov) - Oct 1, 2012
P=N/A, N=25, Completed, Sponsor: University of California, San Francisco
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

||||||||||  fludarabine IV / Generic mfg., busulfan / Generic mfg.
Enrollment change:  Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer (clinicaltrials.gov) -  Sep 30, 2012
P2, N=0, Withdrawn,  Sponsor: University of California, San Francisco
Active, not recruiting --> Completed N=36 --> 0

||||||||||  Inrebic (fedratinib) / BMS
New P2 trial:  Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly (clinicaltrials.gov) -  Sep 23, 2012
P2, N=8, Completed,  Sponsor: Sanofi

||||||||||  ciprofloxacin oral / Generic mfg., amoxycillin/clavulanate / Generic mfg.
Trial termination, Combination therapy, Monotherapy:  Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer (clinicaltrials.gov) -  Sep 19, 2012
P=N/A, N=351, Terminated,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=36 --> 0 Active, not recruiting --> Terminated; low accrual

||||||||||  ciprofloxacin oral / Generic mfg., amoxycillin/clavulanate / Generic mfg.
Enrollment change, Combination therapy, Monotherapy:  Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer (clinicaltrials.gov) -  Sep 19, 2012
P=N/A, N=351, Terminated,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Terminated; low accrual N=530 --> 351

||||||||||  amphotericin b liposome / Generic mfg.
Enrollment change:  Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients (clinicaltrials.gov) -  Sep 19, 2012
P3, N=115, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=530 --> 351 N=450 --> 115

|||||||||| Trial completion: Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant (clinicaltrials.gov) - Sep 19, 2012
P2, N=171, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=450 --> 115 Active, not recruiting --> Completed

||||||||||  amphotericin b liposome / Generic mfg.
Trial completion:  Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients (clinicaltrials.gov) -  Sep 19, 2012
P3, N=115, Completed,  Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  Ojjaara (momelotinib) / GSK
Enrollment closed:  Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) (clinicaltrials.gov) -  Sep 17, 2012
P2, N=120, Active, not recruiting,  Sponsor: Gilead Sciences
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting

||||||||||  luminespib (AUY922) / Ligand
New P2 trial:  HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET (clinicaltrials.gov) -  Aug 15, 2012
P2, N=25, Recruiting,  Sponsor: Memorial Sloan-Kettering Cancer Center

|||||||||| Enrollment change: Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain (clinicaltrials.gov) - Aug 3, 2012
P3, N=98, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
Enrolling by invitation --> Active, not recruiting N=128 --> 98

|||||||||| Trial completion: Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain (clinicaltrials.gov) - Aug 3, 2012
P3, N=98, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
N=128 --> 98 Active, not recruiting --> Completed

||||||||||  Ojjaara (momelotinib) / GSK
Enrollment closed, IO biomarker:  Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (clinicaltrials.gov) -  Jul 17, 2012
P1/2, N=61, Active, not recruiting,  Sponsor: Gilead Sciences
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  gandotinib (LY 2784544) / Eli Lilly
Enrollment open:  Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms (clinicaltrials.gov) -  Jun 13, 2012
P1, N=100, Recruiting,  Sponsor: Eli Lilly and Company
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting

||||||||||  Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed:  Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen (clinicaltrials.gov) -  May 21, 2012
P1/2, N=60, Active, not recruiting,  Sponsor: UNC Lineberger Comprehensive Cancer Center
Not yet recruiting --> Recruiting Completed --> Active, not recruiting

||||||||||  Vonjo (pacritinib) / CTI BioPharma
Trial completion:  A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis (clinicaltrials.gov) -  Apr 18, 2012
P1/2, N=55, Completed,  Sponsor: S*BIO
Completed --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| Enrollment closed, HEOR: Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer (clinicaltrials.gov) - Mar 21, 2012
P=N/A, N=80, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Active, not recruiting --> Completed Recruiting --> Active, not recruiting

||||||||||  Jakafi (ruxolitinib) / Novartis, Incyte
New P4 trial, P2 data:  Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) (clinicaltrials.gov) -  Mar 18, 2012
P4, N=48, Active, not recruiting,  Sponsor: Novartis Pharmaceuticals

||||||||||  fresolimumab (GC 1008) / Sanofi
Enrollment change:  Anti-TGF-beta Therapy in Patients With Myelofibrosis (clinicaltrials.gov) -  Mar 7, 2012
P1, N=3, Completed,  Sponsor: John Mascarenhas
Recruiting --> Active, not recruiting N=14 --> 3

|||||||||| Trial completion: T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Mar 6, 2012
P1, N=20, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
N=14 --> 3 Recruiting --> Completed

||||||||||  decitabine / Generic mfg.
Trial termination:  Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis (clinicaltrials.gov) -  Mar 4, 2012
P2, N=4, Terminated,  Sponsor: Mayo Clinic
Recruiting --> Completed Active, not recruiting --> Terminated; Stopped due to slow accrual

||||||||||  decitabine / Generic mfg.
Enrollment change:  Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis (clinicaltrials.gov) -  Mar 4, 2012
P2, N=4, Terminated,  Sponsor: Mayo Clinic
Active, not recruiting --> Terminated; Stopped due to slow accrual N=22 --> 4

||||||||||  Inrebic (fedratinib) / BMS
Enrollment closed:  Phase 2 Study of SAR302503 in Patients With Myelofibrosis (clinicaltrials.gov) -  Feb 29, 2012
P2, N=30, Active, not recruiting,  Sponsor: Sanofi
N=22 --> 4 Recruiting --> Active, not recruiting

||||||||||  Pegasys (pegylated interferon ? -2a) / Roche
Enrollment open:  MPD-RC 111: Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) (clinicaltrials.gov) -  Feb 28, 2012
P2, N=188, Recruiting,  Sponsor: Ronald Hoffman
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting



	Diseases Companies Products Productz Mechanisms of Action Sites